Aspirin for Primary Prevention of Cardiovascular Disease Events in Diabetes: The Balancing Act?

Abstract

Get full access to this article

View all access options for this article.

References

Roglic

, Unwin

, Bennett

. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28: 2130–5.

Kannel

, McGee

. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2: 120–6.

Anjana

, Unnikrishnan

, Mugilan

. Causes and predictors of mortality in Asian Indians with and without diabetes-10 year follow-up of the Chennai Urban Rural Epidemiology Study (CURES-150). PLoS One 2018; 13:e0197376.

Kovarnik

, Chen

, Mintz

. Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology. Cardiovasc Diabetol 2017; 16:156.

Hajar

. Diabetes as ‘'coronary artery disease risk equivalent'': a historical perspective. Heart Views 2017; 18: 34–7.

Low Wang

, Hess

, Hiatt

. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation 2016; 133: 2459–502.

ASCEND Study Collaborative Group, Bowman L, Mafham M et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379: 1529–39.

Ridker

. Should aspirin be used for primary prevention in post statin era? N Engl J Med 2018; 379: 1572–4.

Campbell

, Smyth

, Montalescot

. Aspirin dose for the prevention of cardiovascular disease: a systemic review. JAMA 2007; 297: 2018–24.

10.

Huang

, Cai

, Mai

. Association between pre-diabetes and risk of cardiovascular disease and all-cause mortality: systemic review and meta-analysis. BMJ 2016; 355: i5953.